The cell and advanced therapy industry has achieved some extraordinary milestones in 2017, culminating with the FDA stating it was committed to encouraging and supporting innovation in the field, and was seeking ways to accelerate the approvals process for new therapies.

With this in mind, cost-effective scale-up and manufacturing remain a key challenge for the industry with a bewildering array of approaches and solutions being pitched to emerging companies. During the Phacilitate Cell & Gene Therapy World Conference in Miami this January, senior members of Invetech’s Cell Therapy Group, David Kneen and Brian Hanrahan, will be joined by industry leaders from Novartis, Kite Pharma and AVROBIO to explore these challenges and discuss the opportunities around selecting a best approach to cost-effective manufacturing and automation.

Plenary Presentation

How to Drive the Cost-Effective Execution of Cell & Gene Therapy Commercialization at the Operational Level

January 23, 2018 from 10:30 to 11:00 am

Panelists: David Kneen (Invetech), Rodney Rietze (Novartis), Jason Jones (Miltenyi Biotec) and Matthew Durdy (Cell and Gene Therapy Catapult, Moderator)

Into Phase I and Phase II, cell therapy companies need to make definitive choices relating to manufacturing. There is no established handover from clinical to commercial manufacturing of cell and gene therapies, therefore decisions made during clinical development will influence the product’s future viability to an unprecedented degree. There is however a path that can be plotted through these complex commercialization challenges with this session to reveal both insights and options.

Invetech's Annual Breakfast Event

Exploring the Value of Proprietary Platforms in Progressing Your Therapy

January 24, 2017 from 7:45 to 8:45 am

Presenters: Rodney Rietze (Novartis), Tim Moore (Kite Pharma), Kim Warren (AVROBIO) and Brian Hanrahan (Invetech, Moderator)

This is your opportunity to participate in a lively discussion around the value of developing proprietary manufacturing platforms and exploring alternative approaches. We have assembled a distinguished panel of industry experts and opinion leaders to explore and discuss approaches and challenges. Our aim for this breakfast event is to enable you to prioritize your thinking and provide you with some of the tools and insight that can assist you in the transition from clinical-scale to commercial-scale manufacturing.